Depression (Major Depressive Disorder) Protocol

Mental HealthStrong Evidence

supplements

Primary

Supporting

Grade A

139

Studies

Primary Stack

Core supplements with strongest evidence

Omega-3 Fatty Acids (EPA)A

1-2g EPA daily (EPA-dominant formula, EPA:DHA ratio >2:1)

EPA reduces neuroinflammation, modulates HPA axis, and enhances serotonin receptor sensitivity and neurotransmission

↓Depression Symptoms↓Postpartum Depression Symptoms

30 studies2,000 participants

Supporting Studies (3)

PMID: 29683153 - Omega-3 fatty acids for depression: meta-analysis (2018)PMID: 31905372 - EPA vs DHA for depression: comparative analysis (2019)PMID: 25532575 - Fish oil supplementation for major depression: systematic review (2014)

St. John's WortA

300mg 3x daily (standardized to 0.3% hypericin)

Inhibits reuptake of serotonin, dopamine, and norepinephrine; modulates GABA receptors

↓Depression Symptoms

35 studies6,000 participants

Supporting Studies (2)

PMID: 27589952 - St John's Wort for depression: Cochrane review (2016)PMID: 25848685 - Hypericum perforatum vs SSRIs: meta-analysis (2015)

Supporting Stack

Additional supplements for enhanced results

SAMe (S-Adenosyl-L-Methionine)A

400-1600mg daily (start low, titrate up)

Methyl donor supporting neurotransmitter synthesis and phospholipid methylation in neuronal membranes

↓Depression SymptomsAttention↑Itching↓Osteoarthritis Symptoms↑Memory

22 studies1,500 participants

Supporting Studies (2)

PMID: 26282172 - SAMe for depression: systematic review and meta-analysis (2015)PMID: 27021968 - SAMe as adjunctive treatment for MDD: RCT (2016)

Vitamin DB

2000-5000 IU daily (target 40-60 ng/mL)

Vitamin D receptors in brain regulate serotonin synthesis; deficiency strongly linked to depression

↓Combined Anxiety & Depression↓Depression Symptoms

25 studies2,000 participants

Supporting Studies (1)

PMID: 24632894 - Vitamin D supplementation for depression: meta-analysis (2014)

Saffron ExtractA

30mg daily (standardized extract)

Crocin and safranal modulate serotonin and dopamine reuptake inhibition with anxiolytic effects

↓Anxiety SymptomsAppetite↓Depression Symptoms↑Sleep Quality↓Homocysteine

15 studies800 participants

Supporting Studies (2)

PMID: 26468457 - Saffron for depression: systematic review (2015)PMID: 23280545 - Saffron vs fluoxetine for depression: RCT (2013)

CurcuminA

500-1000mg daily (enhanced bioavailability form)

Anti-inflammatory effects reduce neuroinflammation; enhances BDNF and modulates monoamine neurotransmitters

↓Anxiety Symptoms↓Depression Symptoms↓Cortisol↓Interleukin 1-beta↑Serum BDNF

12 studies700 participants

Supporting Studies (1)

PMID: 27723543 - Curcumin for depression: meta-analysis (2017)

How This Protocol Works

Simple Explanation

Depression involves complex changes in brain chemistry, inflammation, and neuroplasticity. While severe depression requires professional treatment, several supplements have strong evidence for improving symptoms, either alone for mild-moderate depression or alongside conventional treatment.

•Omega-3 Fatty Acids (EPA) have robust evidence for depression. The brain is highly enriched in omega-3s, and deficiency is linked to depression. EPA specifically reduces neuroinflammation (increasingly recognized as a factor in depression) and enhances serotonin signaling. Studies show significant benefit, especially with EPA-dominant formulas. The effect is strongest in people already on antidepressants (augmentation).

•St. John's Wort is one of the most studied natural antidepressants. It works similarly to prescription antidepressants by preventing the reuptake of serotonin, dopamine, and norepinephrine. Cochrane reviews show it's as effective as SSRIs for mild-moderate depression with fewer side effects. CRITICAL: Do not combine with prescription antidepressants or many other medications—it has major drug interactions.

•SAMe is a natural compound involved in neurotransmitter synthesis. It's been used in Europe for decades as a prescription antidepressant. SAMe supports the production of serotonin, dopamine, and norepinephrine. It works relatively quickly, often within 1-2 weeks. Also beneficial if taking medications that deplete SAMe.

•Vitamin D deficiency is very common in people with depression, and there's evidence the relationship is causal. Vitamin D receptors in the brain regulate genes involved in serotonin synthesis. Supplementation can improve mood, especially in those who are deficient.

•Saffron has surprisingly strong evidence—multiple studies show it's as effective as fluoxetine (Prozac) for mild-moderate depression. It works on serotonin and dopamine systems. It's expensive but effective.

•Curcumin addresses the inflammatory component of depression. Chronic inflammation is increasingly recognized as a driver of depression in many people. Curcumin also increases BDNF (brain-derived neurotrophic factor), which supports neuroplasticity.

Expected timeline: SAMe may show effects within 1-2 weeks. Saffron and curcumin effects typically appear within 4-6 weeks. Omega-3s require 8+ weeks for full benefit. St. John's Wort takes 4-6 weeks.

Clinical Perspective

Major depressive disorder (MDD) pathophysiology involves monoamine deficiency, HPA axis dysregulation, neuroinflammation, reduced BDNF/neuroplasticity, and gut-brain axis dysfunction. Treatment-resistant depression affects 30% of patients. This protocol targets multiple mechanistic pathways.

•Omega-3 Fatty Acids/EPA (A-grade): EPA reduces pro-inflammatory cytokines (IL-6, TNF-alpha) implicated in depression pathophysiology. Incorporates into neuronal membranes affecting receptor function. Enhances serotonin release from presynaptic neurons. Meta-analysis of 30 RCTs: EPA at ≥60% of total EPA+DHA shows significant antidepressant effect (SMD -0.50) (PMID: 29683153). Effect larger as adjunct to antidepressants than monotherapy. DHA alone not effective—EPA is the active component for mood.

•St. John's Wort (Hypericum perforatum) (A-grade): Hyperforin inhibits synaptic reuptake of serotonin, dopamine, norepinephrine, GABA, and glutamate. Hypericin contributes to monoamine oxidase inhibition. Cochrane review of 35 trials (n=6993): superior to placebo (RR 1.48) and equivalent to standard antidepressants for mild-moderate MDD with better tolerability (PMID: 27589952). MAJOR INTERACTIONS: induces CYP3A4, CYP2C9, P-glycoprotein—contraindicated with SSRIs (serotonin syndrome), OCPs, anticoagulants, immunosuppressants, antiretrovirals. Not for severe depression or bipolar.

•SAMe (A-grade): Principal methyl donor in CNS. Required for synthesis of catecholamines, indoleamines, and phosphatidylcholine. Low CSF SAMe levels found in depression. Meta-analysis: superior to placebo; comparable to TCAs with fewer side effects (PMID: 26282172). Effective as adjunct to SSRIs in partial responders (PMID: 27021968). Onset faster than conventional antidepressants (1-2 weeks). Start 400mg/day; titrate to 1600mg. May trigger mania in bipolar—screen before use.

•Vitamin D (B-grade): VDR expressed throughout brain including prefrontal cortex, hippocampus, cingulate gyrus. Calcitriol regulates tryptophan hydroxylase 2 (rate-limiting enzyme in serotonin synthesis). Cross-sectional studies show strong inverse correlation between 25(OH)D and depression. Meta-analysis: supplementation improves depression in those with deficiency (<20 ng/mL) (PMID: 24632894). Target 40-60 ng/mL.

•Saffron (A-grade): Crocin and safranal inhibit serotonin reuptake and possess NMDA receptor antagonist activity. Modulates HPA axis cortisol response. Systematic review of 15 RCTs: as effective as fluoxetine and imipramine for mild-moderate depression (PMID: 26468457). Dose: 30mg/day standardized extract. High cost; ensure authenticity.

•Curcumin (A-grade): Reduces neuroinflammation by inhibiting NF-kB, COX-2, iNOS. Increases serum BDNF levels. Modulates monoamine neurotransmitters. Meta-analysis of 12 RCTs: significant antidepressant effect (SMD -0.75) (PMID: 27723543). Use enhanced bioavailability formulations (piperine, phospholipid complex, nanoparticle).

Biomarker targets: PHQ-9/HAM-D scores, inflammatory markers (CRP, IL-6), omega-3 index, serum 25(OH)D, homocysteine (elevated suggests need for SAMe/B vitamins).

Protocol notes: Mild-moderate depression: monotherapy may suffice. Moderate-severe: consider supplements as adjunct to pharmacotherapy/psychotherapy. St. John's Wort: ABSOLUTELY contraindicated with SSRIs, SNRIs, MAOIs, triptans, tramadol (serotonin syndrome risk). SAMe: contraindicated in bipolar disorder (may trigger mania). Address sleep, exercise (30 min/day as effective as sertraline in some studies), and social connection. Screen for bipolar, substance abuse, thyroid dysfunction, B12 deficiency. Refer for suicidal ideation.

View All Protocols